PI3KInhibitorpi3kinhibitor

Clopidogrel

By

Clopidogrel

Product: Deoxycytidine triphosphate

Identifier : DBSNPE000005
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • C Allele (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : (C;C) / (A;C)
Type(s) : Effect Directly Studied
Groups : Non-functional CYP2C9; Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26. [PubMed:17900275 ]

PMID: 15572027

Clopidogrel

By

Clopidogrel

Product: RA190

Identifier : DBSNPE000006
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • A Allele, homozygote (rs4244285 )

Allele Name : CYP2C19*2
Genotype(s) : (A;A)
Type(s) : Effect Directly Studied
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ: Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26. [PubMed:17900275 ]

PMID: 10368634

Clopidogrel

By

Clopidogrel

Product: Chaetocin

Identifier : DBSNPE000176
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • G > A (rs4244285 )

Allele Name : CYP2C19*2
Genotype(s) : (A;A) / (A;G)
Type(s) : Effect Directly Studied
Groups : Non-functional CYP2C19
Description : Patients are poor metabolizers of clopidogrel. More likely to experience poor cardiovascular outcomes.
References :

  1. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22. [PubMed:8195181 ]
  2. Shuldiner AR, OConnell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, Damcott CM, Pakyz R, Tandivy US, Gibson Q, Pollin TI, Post W, Parsa A, Mitchell BD, Faraday N, Herzog W, Gurbel PA: Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009 Aug 26;302(8):849-57. doi: 10.1001/jama.2009.1232. [PubMed:19706858 ]

PMID: 18441092

Clopidogrel

By

Clopidogrel

Product: Daminozide

Identifier : DBSNPE005144
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2A
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 10762755

Clopidogrel

By

Clopidogrel

Product: 5-Azacytidine

Identifier : DBSNPE005145
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2B
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 16926152

Clopidogrel

By

Clopidogrel

Product: OC000459

Identifier : DBSNPE005146
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 636G>A (rs4986893 )

Allele Name : CYP2C19*3
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 16250663

Clopidogrel

By

Clopidogrel

Product: Kaempferol

Identifier : DBSNPE005147
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1A>G (rs28399504 )

Allele Name : CYP2C19*4
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 22039237

Clopidogrel

By

Clopidogrel

Product: Toremifene (Citrate)

Identifier : DBSNPE005148
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1297C>T (rs56337013 )

Allele Name : CYP2C19*5
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 19422377

Clopidogrel

By

Clopidogrel

Product: Daunorubicin (Hydrochloride)

Identifier : DBSNPE005149
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 395G>A (rs72552267 )

Allele Name : CYP2C19*6
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 10650169

Clopidogrel

By

Clopidogrel

Product: Doxifluridine

Identifier : DBSNPE005150
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 19294T>A (rs72558186 )

Allele Name : CYP2C19*7
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 10963748

Clopidogrel

By

Clopidogrel

Product: Retinoic acid

Identifier : DBSNPE005151
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 557G>C (rs140278421 )
  • 991A>G

Allele Name : CYP2C19*22
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 9683026

Clopidogrel

By

Clopidogrel

Product: Fulvestrant

Identifier : DBSNPE005152
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 99C>T (rs17885098 )
  • 991A>G (rs3758581 )
  • 1004G>A (rs118203757 )
  • 1197A>G

Allele Name : CYP2C19*24
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 24707115

Clopidogrel

By

Clopidogrel

Product: Entacapone

Identifier : DBSNPE005153
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 12662A>G (rs12769205 )

Allele Name : CYP2C19*35
Genotype(s) : Not Available
Type(s) : ADR Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, increased risk for adverse cardiovascular events and lower efficacy. Alternative recommended.
References :

  1. Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR: Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317-23. doi: 10.1038/clpt.2013.105. Epub 2013 May 22. [PubMed:23698643 ]
  2. PLAVIX (clopidogrel bisulfate) tablets[package insert]. Bridgewater, New Jersey: Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership. 2016. [Link]

PMID: 23771238

Clopidogrel

By

Clopidogrel

Product: NVP-LCQ195

Identifier : DBSNPE005587
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 818delA (rs9332131 )

Allele Name : CYP2C9*6
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA: Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics. 2001 Dec;11(9):803-8. [PubMed:11740344 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 2058477

Clopidogrel

By

Clopidogrel

Product: Laquinimod

Identifier : DBSNPE005588
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 485C>A (rs72558190 )

Allele Name : CYP2C9*15
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 2058463

Clopidogrel

By

Clopidogrel

Product: c-FMS inhibitor

Identifier : DBSNPE005589
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 353_362delAGAAATGGAA (rs72558188 )

Allele Name : CYP2C9*25
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 20825409

Clopidogrel

By

Clopidogrel

Product: (R)-5-Hydroxymethyl Tolterodine

Identifier : DBSNPE005590
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>T
  • 430C>T

Allele Name : CYP2C9*35
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Ciccacci C, Falconi M, Paolillo N, Oteri F, Forte V, Novelli G, Desideri A, Borgiani P: Characterization of a novel CYP2C9 gene mutation and sdivuctural bioinformatic protein analysis in a warfarin hypersensitive patient. Pharmacogenet Genomics. 2011 Jun;21(6):344-6. doi: 10.1097/FPC.0b013e328344c340. [PubMed:21451434 ]
  2. Lee MY, Borgiani P, Johansson I, Oteri F, Mkrtchian S, Falconi M, Ingelman-Sundberg M: High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase. Pharmacogenomics J. 2014 Aug;14(4):343-9. doi: 10.1038/tpj.2013.41. Epub 2013 Dec 10. [PubMed:24322786 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 11097381

Clopidogrel

By

Clopidogrel

Product: Calcifediol (monohydrate)

Identifier : DBSNPE005591
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 430C>T (rs1799853 )

Allele Name : CYP2C9*2
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR: Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994 Feb;4(1):39-42. [PubMed:8004131 ]
  2. Crespi CL, Miller VP: The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics. 1997 Jun;7(3):203-10. [PubMed:9241660 ]
  3. Takahashi H, Ieiri I, Wilkinson GR, Mayo G, Kashima T, Kimura S, Otsubo K, Echizen H: 5-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients. Blood. 2004 Apr 15;103(8):3055-7. Epub 2003 Dec 30. [PubMed:15070684 ]
  4. Sandberg M, Johansson I, Christensen M, Rane A, Eliasson E: The impact of CYP2C9 genetics and oral condivaceptives on cytochrome P450 2C9 phenotype. Drug Metab Dispos. 2004 May;32(5):484-9. [PubMed:15100169 ]
  5. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  6. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8695655

Clopidogrel

By

Clopidogrel

Product: MEK inhibitor

Identifier : DBSNPE005592
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C (rs1057910 )

Allele Name : CYP2C9*3
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Sullivan-Klose TH, Ghanayem BI, Bell DA, Zhang ZY, Kaminsky LS, Shenfield GM, Miners JO, Birkett DJ, Goldstein JA: The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics. 1996 Aug;6(4):341-9. [PubMed:8873220 ]
  2. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE: Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, sdivuctural characterization, subsdivate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys. 1996 Sep 15;333(2):447-58. [PubMed:8809086 ]
  3. Aithal GP, Day CP, Kesteven PJ, Daly AK: Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999 Feb 27;353(9154):717-9. [PubMed:10073515 ]
  4. Kidd RS, Sdivaughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT: Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics. 1999 Feb;9(1):71-80. [PubMed:10208645 ]
  5. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K: CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven subsdivates. Pharmacogenetics. 2000 Mar;10(2):95-104. [PubMed:10761997 ]
  6. Shintani M, Ieiri I, Inoue K, Mamiya K, Ninomiya H, Tashiro N, Higuchi S, Otsubo K: Genetic polymorphisms and functional characterization of the 5-flanking region of the human CYP2C9 gene: in vidivo and in vivo studies. Clin Pharmacol Ther. 2001 Aug;70(2):175-82. [PubMed:11503012 ]
  7. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  8. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 7814408

Clopidogrel

By

Clopidogrel

Product: PF-04217903 (methanesulfonate)

Identifier : DBSNPE005593
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1076T>C (rs56165452 )

Allele Name : CYP2C9*4
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Van Booven D, Marsh S, McLeod H, Carrillo MW, Sangkuhl K, Klein TE, Altman RB: Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics. 2010 Apr;20(4):277-81. doi: 10.1097/FPC.0b013e3283349e84. [PubMed:20150829 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19014371

Clopidogrel

By

Clopidogrel

Product: Monomethyl auristatin E

Identifier : DBSNPE005594
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1080C>G (rs28371686 )

Allele Name : CYP2C9*5
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol. 2001 Aug;60(2):382-7. [PubMed:11455026 ]
  2. Allabi AC, Gala JL, Horsmans Y, Babaoglu MO, Bozkurt A, Heusterspreute M, Yasar U: Functional impact of CYP2C95, CYP2C96, CYP2C98, and CYP2C911 in vivo among black Africans. Clin Pharmacol Ther. 2004 Aug;76(2):113-8. [PubMed:15289788 ]
  3. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19023039

Clopidogrel

By

Clopidogrel

Product: VTP-27999 (Hydrochloride)

Identifier : DBSNPE005595
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 449G>A (rs7900194 )

Allele Name : CYP2C9*8
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  3. Liu Y, Jeong H, Takahashi H, Drozda K, Patel SR, Shapiro NL, Nutescu EA, Cavallari LH: Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther. 2012 Apr;91(4):660-5. doi: 10.1038/clpt.2011.269. Epub 2012 Feb 29. [PubMed:22378156 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 9316850

Clopidogrel

By

Clopidogrel

Product: Chenodeoxycholic Acid

Identifier : DBSNPE005596
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1003C>T (rs28371685 )

Allele Name : CYP2C9*11
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Higashi MK, Veensdiva DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, Rettie AE: Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690-8. [PubMed:11926893 ]
  2. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  3. King BP, Khan TI, Aithal GP, Kamali F, Daly AK: Upsdiveam and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics. 2004 Dec;14(12):813-22. [PubMed:15608560 ]
  4. Allabi AC, Gala JL, Horsmans Y: CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics. 2005 Nov;15(11):779-86. [PubMed:16220110 ]
  5. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 7763279

Clopidogrel

By

Clopidogrel

Product: SCH 563705

Identifier : DBSNPE005597
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1465C>T (rs9332239 )

Allele Name : CYP2C9*12
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Blaisdell J, Jorge-Nebert LF, Coulter S, Ferguson SS, Lee SJ, Chanas B, Xi T, Mohrenweiser H, Ghanayem B, Goldstein JA: Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics. 2004 Aug;14(8):527-37. [PubMed:15284535 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19268584

Clopidogrel

By

Clopidogrel

Product: Etodolac

Identifier : DBSNPE005598
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 269T>C (rs72558187 )

Allele Name : CYP2C9*13
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D: Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics. 2004 Jul;14(7):465-9. [PubMed:15226678 ]
  2. Guo Y, Zhang Y, Wang Y, Chen X, Si D, Zhong D, Fawcett JP, Zhou H: Role of CYP2C9 and its variants (CYP2C9*3 and CYP2C9*13) in the metabolism of lornoxicam in humans. Drug Metab Dispos. 2005 Jun;33(6):749-53. Epub 2005 Mar 11. [PubMed:15764711 ]
  3. Guo Y, Wang Y, Si D, Fawcett PJ, Zhong D, Zhou H: Catalytic activities of human cytochrome P450 2C9*1, 2C9*3 and 2C9*13. Xenobiotica. 2005 Sep;35(9):853-61. [PubMed:16308280 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 19136975

Clopidogrel

By

Clopidogrel

Product: Lapatinib (ditosylate)

Identifier : DBSNPE005599
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 374G>A (rs72558189 )

Allele Name : CYP2C9*14
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 22105357

Clopidogrel

By

Clopidogrel

Product: Varenicline (Tartrate)

Identifier : DBSNPE005600
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 895A>G (rs72558192 )

Allele Name : CYP2C9*16
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 27510034

Clopidogrel

By

Clopidogrel

Product: I2906

Identifier : DBSNPE005601
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1075A>C
  • 1190A>C
  • 1425A>T

Allele Name : CYP2C9*18
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Zhao F, Loke C, Rankin SC, Guo JY, Lee HS, Wu TS, Tan T, Liu TC, Lu WL, Lim YT, Zhang Q, Goh BC, Lee SC: Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther. 2004 Sep;76(3):210-9. [PubMed:15371982 ]
  2. DeLozier TC, Lee SC, Coulter SJ, Goh BC, Goldstein JA: Functional characterization of novel allelic variants of CYP2C9 recently discovered in southeast Asians. J Pharmacol Exp Ther. 2005 Dec;315(3):1085-90. Epub 2005 Aug 11. [PubMed:16099926 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 23698760

Clopidogrel

By

Clopidogrel

Product: Varenicline (Hydrochloride)

Identifier : DBSNPE005602
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 389C>G

Allele Name : CYP2C9*26
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 14642775

Clopidogrel

By

Clopidogrel

Product: L-165041

Identifier : DBSNPE005603
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 641A>T

Allele Name : CYP2C9*28
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8013541

Clopidogrel

By

Clopidogrel

Product: Carboxypeptidase G2 (CPG2) Inhibitor

Identifier : DBSNPE005604
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 1429G>A

Allele Name : CYP2C9*30
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J: Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics. 2006 Jul;16(7):497-514. [PubMed:16788382 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 8220906

Clopidogrel

By

Clopidogrel

Product: Nortadalafil

Identifier : DBSNPE005605
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C9
Gene Name : CYP2C9
UniProt ID : P11712
Defining Change(s) :

  • 395G>A (rs200183364 )

Allele Name : CYP2C9*33
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Decreased CYP2C9
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Yin T, Maekawa K, Kamide K, Saito Y, Hanada H, Miyashita K, Kokubo Y, Akaiwa Y, Otsubo R, Nagatsuka K, Otsuki T, Horio T, Takiuchi S, Kawano Y, Minematsu K, Naritomi H, Tomoike H, Sawada J, Miyata T: Genetic variations of CYP2C9 in 724 Japanese individuals and their impact on the antihypertensive effects of losartan. Hypertens Res. 2008 Aug;31(8):1549-57. doi: 10.1291/hypres.31.1549. [PubMed:18971529 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 16129772

Clopidogrel

By

Clopidogrel

Product: Fesoterodine (fumarate)

Identifier : DBSNPE005606
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2A
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. de Morais SM, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA: The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem. 1994 Jun 3;269(22):15419-22. [PubMed:8195181 ]
  2. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada J: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005 Aug;20(4):300-7. [PubMed:16141610 ]
  3. Lee SJ, Kim WY, Kim H, Shon JH, Lee SS, Shin JG: Identification of new CYP2C19 variants exhibiting decreased enzyme activity in the metabolism of S-mephenytoin and omeprazole. Drug Metab Dispos. 2009 Nov;37(11):2262-9. doi: 10.1124/dmd.109.028175. Epub 2009 Aug 6. [PubMed:19661214 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 16041400

Clopidogrel

By

Clopidogrel

Product: NVP-BKM120 (Hydrochloride)

Identifier : DBSNPE005607
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 681G>A (rs4244285 )

Allele Name : CYP2C19*2B
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5. [PubMed:9732415 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 1562721

Clopidogrel

By

Clopidogrel

Product: Vernakalant (Hydrochloride)

Identifier : DBSNPE005608
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 636G>A (rs4986893 )

Allele Name : CYP2C19*3
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994 Oct;46(4):594-8. [PubMed:7969038 ]
  2. Fukushima-Uesaka H, Saito Y, Maekawa K, Ozawa S, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Tohkin M, Sawada J: Genetic variations and haplotypes of CYP2C19 in a Japanese population. Drug Metab Pharmacokinet. 2005 Aug;20(4):300-7. [PubMed:16141610 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 2456068

Clopidogrel

By

Clopidogrel

Product: Furagin

Identifier : DBSNPE005609
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1A>G (rs28399504 )

Allele Name : CYP2C19*4
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA: A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther. 1998 Jan;284(1):356-61. [PubMed:9435198 ]
  2. Scott SA, Martis S, Peter I, Kasai Y, Kornreich R, Desnick RJ: Identification of CYP2C19*4B: pharmacogenetic implications for drug metabolism including clopidogrel responsiveness. Pharmacogenomics J. 2012 Aug;12(4):297-305. doi: 10.1038/tpj.2011.5. Epub 2011 Mar 1. [PubMed:21358751 ]
  3. Zackrisson AL, Lindblom B, Ahlner J: High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating uldivarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010 Sep;88(3):354-9. doi: 10.1038/clpt.2009.216. Epub 2009 Nov 11. [PubMed:19907421 ]
  4. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 22284362

Clopidogrel

By

Clopidogrel

Product: ST 2825

Identifier : DBSNPE005610
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 1297C>T (rs56337013 )

Allele Name : CYP2C19*5
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Xiao ZS, Goldstein JA, Xie HG, Blaisdell J, Wang W, Jiang CH, Yan FX, He N, Huang SL, Xu ZH, Zhou HH: Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther. 1997 Apr;281(1):604-9. [PubMed:9103550 ]
  2. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Daly AK, Goldstein JA: An additional defective allele, CYP2C19*5, condivibutes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics. 1998 Apr;8(2):129-35. [PubMed:10022751 ]
  3. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 25605330

Clopidogrel

By

Clopidogrel

Product: ALK inhibitor 2

Identifier : DBSNPE005611
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 395G>A (rs72552267 )

Allele Name : CYP2C19*6
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, Ghanayem BI, Blaisdell J: Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. J Pharmacol Exp Ther. 1998 Sep;286(3):1490-5. [PubMed:9732415 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 15371556

Clopidogrel

By

Clopidogrel

Product: VU 0357121

Identifier : DBSNPE005612
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 19294T>A (rs72558186 )

Allele Name : CYP2C19*7
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Ibeanu GC, Blaisdell J, Ferguson RJ, Ghanayem BI, Brosen K, Benhamou S, Bouchardy C, Wilkinson GR, Dayer P, Goldstein JA: A novel divansversion in the indivon 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 condivibute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. J Pharmacol Exp Ther. 1999 Aug;290(2):635-40. [PubMed:10411572 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 23094097

Clopidogrel

By

Clopidogrel

Product: MPEP

Identifier : DBSNPE005613
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 557G>C (rs140278421 )
  • 991A>G

Allele Name : CYP2C19*22
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Takahashi M, Saito T, Ito M, Tsukada C, Katono Y, Hosono H, Maekawa M, Shimada M, Mano N, Oda A, Hirasawa N, Hiratsuka M: Functional characterization of 21 CYP2C19 allelic variants for clopidogrel 2-oxidation. Pharmacogenomics J. 2015 Feb;15(1):26-32. doi: 10.1038/tpj.2014.30. Epub 2014 Jul 8. [PubMed:25001882 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 21390306

Clopidogrel

By

Clopidogrel

Product: MPEP (Hydrochloride)

Identifier : DBSNPE005614
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 99C>T (rs17885098 )
  • 991A>G (rs3758581 )
  • 1004G>A (rs118203757 )
  • 1197A>G

Allele Name : CYP2C19*24
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Zhou Q, Yu XM, Lin HB, Wang L, Yun QZ, Hu SN, Wang DM: Genetic polymorphism, linkage disequilibrium, haplotype sdivucture and novel allele analysis of CYP2C19 and CYP2D6 in Han Chinese. Pharmacogenomics J. 2009 Dec;9(6):380-94. doi: 10.1038/tpj.2009.31. Epub 2009 Jul 28. [PubMed:19636337 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 10372831

Clopidogrel

By

Clopidogrel

Product: Lonafarnib

Identifier : DBSNPE005615
Drug : DB00758 (Clopidogrel)
Interacting Gene/Enzyme : Cytochrome P450 2C19
Gene Name : CYP2C19
UniProt ID : P33261
Defining Change(s) :

  • 12662A>G (rs12769205 )

Allele Name : CYP2C19*35
Genotype(s) : Not Available
Type(s) : Effect Inferred
Groups : Non-functional CYP2C19
Description : Poor drug metabolizer, lower dose requirements, higher risk for drug-drug interactions
References :

  1. Chaudhry AS, Prasad B, Shirasaka Y, Fohner A, Finkelstein D, Fan Y, Wang S, Wu G, Aklillu E, Sim SC, Thummel KE, Schuetz EG: The CYP2C19 Indivon 2 Branch Point SNP is the Ancesdival Polymorphism Condivibuting to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles. Drug Metab Dispos. 2015 Aug;43(8):1226-35. doi: 10.1124/dmd.115.064428. Epub 2015 May 28. [PubMed:26021325 ]
  2. The Human Cytochrome P450 (CYP) Allele Nomenclature Database [Link]

PMID: 9631241

By

Related Post

You Missed

Uncategorized

Immunoprecipitated with an anti-HMGCoAR antibody, then probed with anti-ubiquitin antibody. As

Uncategorized

Genes, IAP and XIAP. IAP-1 mRNA levels increased by 111.7.5 in the

Uncategorized

Improved Th17 and T follicular helper cell development, early onset experimental

Uncategorized

Ls) have been solubilized in 1 ml of lysis/immunoprecipitation buffer (150 mM NaCl